17 hrs ago
EMA recommends full marketing approval for IMBRUVICA in the European Union
Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA in the European Union.
Profits and capacity utilisation up at Lonza in H1 thanks to pharma
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
Biomedical engineer looks at new applications for novel lupus drug
Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.
The Motley Fool
Is Gilead About to Crush Pharmacyclics Stock?
However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.
Pharmacyclics estimates raised ahead of Q2 report at Goldman
Pharmacyclics estimates raised ahead of Q2 report at Goldman Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data.
Pharmacyclics Receives Outperform Rating from Credit Suisse
's stock had its "outperform" rating restated by analysts at Credit Suisse in a research report issued to clients and investors on Monday.